Channel: Dr. John Campbell

Category: Education

Tags: human biologydiseasebiologymedical educationphysiologyhealthnursingmedicinehuman bodycampbellnclexpathophysiologynurse education

Description: Bottom line, Im not worried, but it is interesting VOCs What is XE? assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1063424/Tech-Briefing-39-25March2022_FINAL.pdf deadline.com/wp-content/uploads/2022/03/20220329_Weekly_Epi_Update_85.pdf XE strain is a recombinant variant of BA.1 and BA.2 Mutation An error is incorporated in the viral genome Recombination Coinfecting viruses exchange genetic information, creating a novel virus Changes to variant classification system Variant of Concern label a detrimental change in biological properties (changes in transmissibility, severity or immune evasion) compared to the current dominant variant(s); and a growth rate potentially compatible with maintaining transmission and/or displacing the current dominant variant. designate new variants based on genomic features and growth X = BA.1 E = BA.2 X = Delta F = Delta Two are a combination of Delta and BA.1 XD and XF XD, few cases detected in France, Belgium, Denmark XT, small cluster detected in UK, (before 15th Feb) One recombination of BA.1 and BA.2 XE is a BA.1/BA.2 recombinant XE evidence of community transmission within England currently less than 1% of total sequenced cases Using the most recent data up to 16 March 2022 XE has a growth rate 9.8% above that of BA.2 Per week XE biology 763 XE sequences in the UK data XE is a BA.1 and BA.2 recombinant 3 mutations that are not present in all BA.1 or BA.2 sequences BA.2 latest SGTP is a reasonable proxy for BA.2 England on 20 March 2022, 93.7% BA.2 England on 6th March 2022, 82.6% BA.2 Growth rate of BA.2 Increased growth rate compared to BA.1 in all regions of England Growth rate, 75% greater relative growth for BA.2 compared to BA.1. GR = 0.753 per week Hospitalisation No evidence of a greater risk of hospitalisation following infection with BA.2 compared to BA.1. SARS-CoV-2 Immunity and Reinfection EvaluatioN (SIREN) 90 day gap N = 44,000 healthcare workers, recruited from 135 sites Now highly vaccinated (more than 95%) Two weekly PVR testing 27th December 2021 to 16th January 2022 N = 496,228 cases of PCR confirmed SARS-CoV-2 infection 186,896 BA.1 confirmed cases with genome sequencing Thirty-one of these cases had another subsequent sequenced but there are no early indications of a specific reinfection issue with this scenario.